About GenMark Diagnostics
GenMark Diagnostics is a Healthcare company based in San Diego (United States) founded in 1993, and was acquired by Roche in March 2021. Instruments and test panels for multiplexed molecular diagnostics are provided. GenMark Diagnostics has raised $8.56 million across 2 funding rounds from investors including Roche and SLR Investment Corp. The company has 797 employees. GenMark Diagnostics offers products and services including ePlex System and ePlex Cartridge. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is Roche Diagnostics, North America. Its competitors include Inflammatix, Visby Medical and T2 Biosystems; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1993 in San Diego, United States, multiplexed molecular diagnostics are supported through instruments and test panels. The ePlex System incorporates digital microfluidics for PCR-based assays, with results obtained in under 90 minutes. Disposable cartridges in the XT-8 system enable analyte measurement via electrochemical sensors. Test panels are developed for CNS, GI, respiratory, and hepatic infections, along with genetic disorders.
- Headquarters San Diego, United States
- Employees 797
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genmarkdx.com
- Social LinkedIn
- Acquired by Roche (Mar 2021)
- Legal Name Roche Diagnostics, North America
- Annual Revenue$171.55 M (USD)95as on Dec 31, 2020
- Net Profit-$18.64 M (USD)61as on Dec 31, 2020
- EBITDA-$11.05 M (USD)74as on Dec 31, 2020
- Total Equity Funding$8.56M (USD)
in 2 rounds
- Latest Funding Round$65M (USD), Debt – Conventional
Feb 2019
- InvestorsRoche
& 1 more
- Employee Count797
- Acquired byRoche
(Mar 2021)
Products & Services of GenMark Diagnostics
GenMark Diagnostics offers a comprehensive portfolio of products and services, including ePlex System and ePlex Cartridge.
Automates nucleic acid testing for pathogen detection.
Enables single-use molecular assays for diagnostics.
Funding Insights of GenMark Diagnostics
GenMark Diagnostics has successfully raised a total of $8.56M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $65 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.56M
- Total Rounds 2
- Last Round Debt – Conventional — $65M
- First Round $8.56M
(Dec 2009)
- Investors Count 1
All 2 funding rounds of GenMark Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $65M | Debt – Conventional | – | – | |
| Dec 2009 | $8.56M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in GenMark Diagnostics
GenMark Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche and SLR Investment Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Debt and equity investments are offered by the firm. | 2006 | solarcapltd.com | New York, United States | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for GenMark Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GenMark Diagnostics
131 people are tracked at GenMark Diagnostics (23 in leadership, 108 in team); the tracked headcount is 797.
| Name | Role | Group |
|---|---|---|
Mirco Woldert | Head, Finance, IT & Facilities | Leadership |
Beth Stofka Ms, Rac | Director, Regulatory Affairs | Leadership |
Jeremy Kiger | Head, Product Strategy & International Business | Leadership |
Debra Shane | Sr. Director, Operations | Leadership |
Michael Nguyen | Director Software Engineering | Leadership |
Manfred Schwenk | Head, Operations | Leadership |
Tanya Monga | CEO | Leadership |
Msph Ali Mohammadian Cih | Director - Ehs, Facilities, & Security | Leadership |
John Wilson | Area Sales Director | Leadership |
Ankur Shah | Senior Director, Assay Development | Leadership |
Fred Spiess | Associate Director, Product Engineering | Leadership |
Peter Serpentino | Vice President Business Development | Leadership |
Teena Dean | Director, Corporate Accounts | Leadership |
Al Maderazo | VP, Quality, Regulatory, & Clinical Affairs | Leadership |
Matt Friedenberg | Head Of Research And Development | Leadership |
Karen Menge | Senior Director Assay Development | Leadership |
Minnie Coley | Senior Executive Assistant To CEO At Genmark Diagnostics, A Member Of The Roche Group | Leadership |
Kristina Schimmelpfeng Henthorn | Head Of Operations Quality Control | Leadership |
Bob K. | Sr. Director, Lifecycle Management | Leadership |
Bradley Brown | Senior Director Assay Development | Leadership |
111 more people are available in the full profile.
Complete people profiles for GenMark Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GenMark Diagnostics
5 dated milestones of GenMark Diagnostics across 28 years, from founding to its latest funding, stage changes and deals.
- Founded GenMark Diagnostics is founded.
- Funding First funding round of $8.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $65.0M.
- Exit Acquired by Roche.
Competitors of GenMark Diagnostics
GenMark Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Visby Medical and T2 Biosystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. |
Detailed competitors of GenMark Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GenMark Diagnostics
Websites that share an audience with GenMark Diagnostics (genmarkdx.com).
Websites whose visitors overlap most with GenMark Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cepheid.com | 100% | 117.9K | #496,659 | View details | |
promtest.am | promtest.am | 63% | #2,748,947 | – | |
blue.regence.com | blue.regence.com | 62% | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GenMark Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genmark Diagnostics
Complete news archive for GenMark Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenMark Diagnostics
GenMark Diagnostics was founded in 1993 and raised its 1st funding round 16 years after it was founded.
GenMark Diagnostics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
GenMark Diagnostics is a funded company, having raised a total of $8.56M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.56M, raised on Dec 2009.
GenMark Diagnostics has 797 employees.
Annual revenue of GenMark Diagnostics is $171.55M as on Dec 31, 2020.
Founded in 1993 in San Diego, United States, multiplexed molecular diagnostics are supported through instruments and test panels. The ePlex System incorporates digital microfluidics for PCR-based assays, with results obtained in under 90 minutes. Disposable cartridges in the XT-8 system enable analyte measurement via electrochemical sensors. Test panels are developed for CNS, GI, respiratory, and hepatic infections, along with genetic disorders.
GenMark Diagnostics's top competitors include Visby Medical, Inflammatix and T2 Biosystems.
GenMark Diagnostics offers ePlex System and ePlex Cartridge.
GenMark Diagnostics has 2 investors. Key investors include Roche, and SLR Investment Corp.
GenMark Diagnostics operates through Roche Diagnostics, North America.
Yes. GenMark Diagnostics was acquired by Roche in March 2021.